Healthcare entity
All 1 tracked stories fall under one category: medical-devices. Paolo De Coppi is most often covered alongside Great Ormond Street Hospital, which appears in 1 of these 1 story. Their average consequence score of 8 runs above the beat's 6.3 for that window.
Last mentioned: Mar 20, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 1 tracked stories fall under one category: medical-devices. Paolo De Coppi is most often covered alongside Great Ormond Street Hospital, which appears in 1 of these 1 story. Their average consequence score of 8 runs above the beat's 6.3 for that window. Source depth averages 3 original sources per story, versus 2.9 across the same-window beat baseline. We currently track 1 Healthcare story that mention Paolo De Coppi, all published on March 20, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 23 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Paolo De Coppi. Shared-story counts are live from our verified record — not editorial picks.
Commercial Scalability Assessment
Evaluation of bio-foundry partnerships to standardize the production of engineered scaffolds.
Regulatory Submission
Expected filing for Advanced Therapy Medicinal Product (ATMP) designation with the MHRA.
Expanded Clinical Trials
Anticipated start of Phase II trials involving a larger cohort of pediatric patients with long-gap OA.
Breakthrough Announcement
First successful lab-grown oesophagus for pediatric use is unveiled to the public.
Researchers have successfully engineered the first lab-grown oesophagus, providing a transformative solution for children born with Oesophageal Atresia. This tissue-engineered breakthrough uses a patient's own cells to create a functional organ, potentially eliminating the need for high-risk invasive surgeries.
Source: oxfordmail.co.uk · london-now.co.uk
Paolo De Coppi is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
